OncoMatch/Clinical Trials/NCT05470777
CD22/CD19 CAR-T and Auto-HSCT Sandwich Strategy as Consolidation Therapy for B-ALL
Is NCT05470777 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies CD22/CD19 CAR T and auto-HSCT "sandwich" strategy for b-cell acute lymphoblastic leukemia.
Treatment: CD22/CD19 CAR T and auto-HSCT "sandwich" strategy — Chimeric antigen receptor T-cell (CAR-T) therapy has achieved remarkable efficacy in B-cell acute lymphoblastic leukemia (B-ALL). However, relapse after CAR-T has been a major issue. Multi-antigen CAR T and combination with other regimens may reduce the relapse rate. The investigators first conducted CD22/CD19 CAR T-cells and auto-HSCT "sandwich " strategy as consolidation therapy in patients with B-ALL. The main Purpose of this study was to observe the safety and efficacy of this new strategy.
Check if I qualifyExtracted eligibility criteria
Cancer type
Acute Lymphoblastic Leukemia
Biomarker criteria
Required: CD19 positive expression (positive)
positive expression of CD19 and CD22 in peripheral blood or bone marrow primary cells detected by flow cytometry
Required: CD22 positive expression (positive)
positive expression of CD19 and CD22 in peripheral blood or bone marrow primary cells detected by flow cytometry
Prior therapy
Cannot have received: anti-CD19 therapy
previously treated with anti-CD19
Cannot have received: anti-CD22 therapy
previously treated with ... CD22
Cannot have received: anti-CD3 therapy
previously treated with ... CD3 therapies
Lab requirements
Kidney function
creatinine ≤ 1.6 mg/dl
Liver function
alt and ast ≤ 3 times the normal range and total bilirubin ≤ 2.0 mg/dl
Cardiac function
cardiac ultrasound left ventricular ejection fraction ≥ 50%
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify